Holen Sie sich die Stockscreener-App
2.3897
7.42%
0.1647
Schlusskurs vom Vortag:
$2.225
Offen:
$2.27
24-Stunden-Volumen:
72,528
Relative Volume:
0.19
Marktkapitalisierung:
$28.19M
Einnahmen:
$152.40K
Nettoeinkommen (Verlust:
$-10.52M
KGV:
-0.9585
EPS:
-2.4931
Netto-Cashflow:
$-4.26M
1W Leistung:
+16.02%
1M Leistung:
+74.45%
6M Leistung:
+305.08%
1J Leistung:
+191.50%
1-Tages-Spanne:
$2.27
$2.39
1-Wochen-Bereich:
$2.12
$2.70
52-Wochen-Spanne:
$0.40
$2.70
Abvc Biopharma Inc Stock (ABVC) Company Profile
Firmenname
Abvc Biopharma Inc
Sektor
Branche
Telefon
510-668-0881
Adresse
44370 OLD WARM SPRINGS BLVD., FREMONT
Vergleichen Sie ABVC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABVC
Abvc Biopharma Inc
|
2.39 | 28.19M | 152.40K | -10.52M | -4.26M | -2.4931 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.17 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
523.95 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
323.16 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
562.09 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
242.13 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Abvc Biopharma Inc Aktie (ABVC) Neueste Nachrichten
ABVC BioPharma's Affiliate OncoX Acquires Lycopenoid Platform to Strengthen Oncology Portfolio - citybuzz -
ABVC BioPharma Expands Oncology Portfolio as Affiliate OncoX Acquires Patented Lycopenoid Platform Valued at $4.06 Million - The Globe and Mail
ABVC BioPharma Shareholders Approve Key Proposals - TipRanks
ABVC BioPharma Announces Board Approval of Share Dividend Showing Confidence in Subsidiary Growth and Long-Term Shareholder Value - Yahoo Finance
ABVC BioPharma, Inc. (NASDAQ:ABVC) Short Interest Up 40.0% in May - Defense World
3 Top Growth Stocks to Buy in the Second Half of 2025 - The Globe and Mail
ABVC BioPharma Files $100 Million Mixed Shelf - marketscreener.com
ABVC BioPharma Regains Nasdaq Minimum Bid Price Compliance - Yahoo Finance
ABVC BioPharma Secures Japanese Patent for Botanical Depression Treatment - citybuzz -
ABVC BioPharma Secures Japanese Patent for Its Natural MDD Treatment Candidate ABV-1504 - Yahoo Finance
ABVC BioPharma Announces First Quarter 2025 Financial Results and Strategic Planning for AI-Driven Agricultural Project in Taiwan - Yahoo Finance
ABVC BIOPHARMA, INC. SEC 10-Q Report - TradingView
ABVC BioPharma and AiBtl BioPharma's Worldwide Business Development Team Participate in the 43rd Annual J.P. Morgan Healthcare Conference - The Globe and Mail
UPDATE: ABVC BioPharma Announces 2024 Financial Results - Yahoo Finance
ABVC BioPharma Reports Strong Financial Growth - TipRanks
ABVC Biopharma Concluded That Financial Statements For FY Ended Dec 31, 2023 Should No Longer Be Relied Upon Due To Errors In Financial Statements - marketscreener.com
ABVC BioPharma Announces 2024 Financial Results - Yahoo Finance
ABVC BIOPHARMA, INC. SEC 10-K Report - TradingView
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
ABVC Subsidiary Acquires Taiwanese Land to Secure Botanical Drug Production - citybuzz -
ABVC's Subsidiary AiBtl Signs Share-for-Land Agreement in Asia With Deal Valued at USD $7.67 Million - Yahoo Finance
How analysts predict ABVC BioPharma Inc (ABVC) will perform this quarter? - uspostnews.com
ABVC BioPharma Delays Yearly Report Filing - TipRanks
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
ABVC BioPharma, Inc. (NASDAQ:ABVC) Short Interest Down 22.7% in March - Defense World
ABVC BioPharma Maintains Lucrative Global Licensing Agreements and Promising CDMO Acquisition, Strengthening Growth Potential - Yahoo Finance
ABVC BioPharma, Inc. (NASDAQ:ABVC) Sees Significant Growth in Short Interest - The AM Reporter
ABVC BioPharma, Inc. (NASDAQ:ABVC) Short Interest Update - Defense World
ABVC BioPharma announces CFO resignation, CEO steps in as interim By Investing.com - Investing.com Canada
ABVC BioPharma announces CFO resignation, CEO steps in as interim - Investing.com India
ABVC Biopharma Inc On March 5, Leeds Chow Resigns As CFO Of Abvc Biopharma - Marketscreener.com
ABVC BioPharma Plans to Expand Investment in U.S. for Production Facilities and Products for Unmet Medical Needs - Financial Content
ABVC BioPharma's CEO Discusses New Drug Development and AI Integration - ACCESS Newswire
ABVC and BioLite Japan Forge Strategic Alliance to Boost Japanese Biotech Global Expansion - citybuzz -
ABVC and BioLite Japan Implement Strategy to Advance Japan's Biotech Innovation Into Global Markets - Financial Content
ABVC BioPharma Announces Potential $7M Cash Licensing Income from Existing Agreements in 2025 - Yahoo Finance
Attention Deficit Hyperactivity Disorder Treatment Market - openPR.com
Positive Market Response in Asia Fuels Potential Revenue Growth for ABVC and BioKey, Marching Into Global Dietary Supplements Market of USD 75.35 Billion - Yahoo Finance
ABVC BioPharma, Inc. (NASDAQ:ABVC) Sees Large Decline in Short Interest - Defense World
ABVC BioPharma, Inc. (NASDAQ:ABVC) Short Interest Down 42.6% in December - Defense World
ABVC BioPharma s ADHD and MDD Drug Polygala Tenuifolia a Natural Wonder With Potential of Transforming Mental Health Treatment of More Than 30 Billion Market - Yahoo Finance
AiBtl BioPharma Strengthens Partnership With ABVC BioPharma, Paying $150,000 in Licensing Fees - Yahoo Finance
Head to Head Review: ABVC BioPharma (NASDAQ:ABVC) vs. Rhythm Pharmaceuticals (NASDAQ:RYTM) - Defense World
ABVC BioPharma, Inc. Granted Additional 180-Day Grace Period to Regain Compliance With Nasdaq Bid Price Requirement - Yahoo Finance
ABVC BioPharma and ForSeeCon: An Update on Alliance's Ophthalmology-Related Products - Yahoo Finance
ABVC BioPharma Expands Global Patent Portfolio for ADHD Treatment - Citybuzz
ABVC BioPharma Secures an Additional Patent for ADHD Treatment, in Addition to the Granted U.S. and Australian Patents, Moving Forward to the Global Patent Map of $32.14 Billion Potential Market - Yahoo Finance
Short Interest in ABVC BioPharma, Inc. (NASDAQ:ABVC) Rises By 148.2% - Defense World
Finanzdaten der Abvc Biopharma Inc-Aktie (ABVC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.77%
0.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):